Intestino permeable. Importancia para la salud y bienestar
Leaky gut. Importance for health and well-being
Palabras clave:
disbiosis, barrera intestinal, probiótico
Resumen
La microbiota intestinal mantiene la integridad de esta barrera intestinal. La disbiosis intestinal se manifiesta por presencia de cepas bacterianas proinflamatorias, como las especies Bacteroides. Existen 3 formas de modular la composición de la microbiota intestinal: suplementación con probióticos, Intervención con especies microbianas específicas utilizando medicamentos y trasplante fecal con microbioma intestinal sano. El desarrollo de nuevas herramientas terapéuticas que modifiquen la composición de la microbiota intestinal permitirá a futuro poder controlar un numeroso grupo de enfermedades.
Descargas
La descarga de datos todavía no está disponible.
Citas
Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. (2021)19:55–71.
Mu Q, Kirby J, Reilly CM, Luo XM. Leaky gut as a danger signal for autoimmune diseases. Front Immunol. 2017;8:598.
Belizario JE, Faintuch J, Garay-Malpartida M. Gut microbiome dysbiosis and immunometabolism: new frontiers for treatment of metabolic diseases. MediatInflamm 2018:2037838.
Yang G, Wei J, Liu P, Zhang Q, Tian Y, Hou G, et al. Role of the gut microbiota in type 2 diabetes and related diseases. Metabolism. (2021) 117:154712: 154712.
Takiishi T, Fenero CIM, Camara NOS. Intestinal barrier and gut microbiota: shaping our immune responses throughout life. Tissue Barriers. (2017) 5:e1373208.
Pasini E, Corsetti G, Assanelli D, Testa C, Romano C, Dioguardi FS, et al. Effects of chronic exercise on gut microbiota and intestinal barrier in human with type 2 diabetes. Minerva Med. (2019) 110:3–11.
Sharma S, Tripathi P. Gut microbiome and type 2 diabetes: where we are and where to go? J Nutr Biochem. (2019) 63:101–8.
Salazar J, Angarita L, Morillo V, Navarro C, Martinez MS, Chacin M, et al. Microbiota and diabetes mellitus: role of lipid mediators. Nutrients. (2020) 12:3039.
Han Y, Wu L, Ling Q, Wu P, Zhang C, Jia L, et al. Intestinal dysbiosis correlates with sirolimus-induced metabolic disorders in mice. Transplantation. (2021) 105:1017–29.
Zhou J, Li M, Chen Q, Li X, Chen L, Dong Z, et al. Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery. Nat Commun. (2022) 13:3432: 3432.
Zhou D, Pan Q, Shen F, Cao HX, Ding WJ, Chen YW, et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep. (2017) 7:1529: 1529.
Delaune V, Orci LA, Lacotte S, Peloso A, Schrenzel J, Lazarevic V, et al. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response. Expert Opin Biol Ther. (2018) 18:1061–71.
Li Y, Liu T, Yan C, Xie R, Guo Z, Wang S, et al. Diammonium glycyrrhizinate protects against nonalcoholic fatty liver disease in mice through modulation of gut microbiota and restoration of intestinal barrier. Mol Pharm. (2018) 15:3860–70.
Xu W, Lin L, Liu A, Zhang T, Zhang S, Li Y, et al. L-Theanine affects intestinal mucosal immunity by regulating short-chain fatty acid metabolism under dietary fiber feeding. Food Funct. (2020 Sep 23)11:8369–79.
Chang CJ, Lin CS, Lu CC, Martel J, Ko YF, Ojcius DM, et al. Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota. Nat Commun. (2015) 6:7489.
Xie WR, Yang XY, Deng ZH, Zheng YM, Zhang R, Wu LH, et al. Effects of washed microbiota transplantation on serum uric acid levels, symptoms, and intestinal barrier function in patients with acute and recurrent gout: a pilot study. Dig Dis. (2022) 40:684–90.
Weston KS, Wisloff U, Coombes JS. High-intensity interval training in patients with lifestyle-induced cardiometabolic disease: a systematic review and meta-analysis. Br J Sports Med. (2014) 48:1227– 34.
Guzman A, Navarro E, Obando L, Pacheco J, Quiros K, Vasquez L, et al. Effectiveness of interventions for the reversal of a metabolic syndrome diagnosis: an update of a meta-analysis of mixed treatment comparison studies. Biomedica. (2019) 39:647–62.
Mu Q, Kirby J, Reilly CM, Luo XM. Leaky gut as a danger signal for autoimmune diseases. Front Immunol. 2017;8:598.
Belizario JE, Faintuch J, Garay-Malpartida M. Gut microbiome dysbiosis and immunometabolism: new frontiers for treatment of metabolic diseases. MediatInflamm 2018:2037838.
Yang G, Wei J, Liu P, Zhang Q, Tian Y, Hou G, et al. Role of the gut microbiota in type 2 diabetes and related diseases. Metabolism. (2021) 117:154712: 154712.
Takiishi T, Fenero CIM, Camara NOS. Intestinal barrier and gut microbiota: shaping our immune responses throughout life. Tissue Barriers. (2017) 5:e1373208.
Pasini E, Corsetti G, Assanelli D, Testa C, Romano C, Dioguardi FS, et al. Effects of chronic exercise on gut microbiota and intestinal barrier in human with type 2 diabetes. Minerva Med. (2019) 110:3–11.
Sharma S, Tripathi P. Gut microbiome and type 2 diabetes: where we are and where to go? J Nutr Biochem. (2019) 63:101–8.
Salazar J, Angarita L, Morillo V, Navarro C, Martinez MS, Chacin M, et al. Microbiota and diabetes mellitus: role of lipid mediators. Nutrients. (2020) 12:3039.
Han Y, Wu L, Ling Q, Wu P, Zhang C, Jia L, et al. Intestinal dysbiosis correlates with sirolimus-induced metabolic disorders in mice. Transplantation. (2021) 105:1017–29.
Zhou J, Li M, Chen Q, Li X, Chen L, Dong Z, et al. Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery. Nat Commun. (2022) 13:3432: 3432.
Zhou D, Pan Q, Shen F, Cao HX, Ding WJ, Chen YW, et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep. (2017) 7:1529: 1529.
Delaune V, Orci LA, Lacotte S, Peloso A, Schrenzel J, Lazarevic V, et al. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response. Expert Opin Biol Ther. (2018) 18:1061–71.
Li Y, Liu T, Yan C, Xie R, Guo Z, Wang S, et al. Diammonium glycyrrhizinate protects against nonalcoholic fatty liver disease in mice through modulation of gut microbiota and restoration of intestinal barrier. Mol Pharm. (2018) 15:3860–70.
Xu W, Lin L, Liu A, Zhang T, Zhang S, Li Y, et al. L-Theanine affects intestinal mucosal immunity by regulating short-chain fatty acid metabolism under dietary fiber feeding. Food Funct. (2020 Sep 23)11:8369–79.
Chang CJ, Lin CS, Lu CC, Martel J, Ko YF, Ojcius DM, et al. Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota. Nat Commun. (2015) 6:7489.
Xie WR, Yang XY, Deng ZH, Zheng YM, Zhang R, Wu LH, et al. Effects of washed microbiota transplantation on serum uric acid levels, symptoms, and intestinal barrier function in patients with acute and recurrent gout: a pilot study. Dig Dis. (2022) 40:684–90.
Weston KS, Wisloff U, Coombes JS. High-intensity interval training in patients with lifestyle-induced cardiometabolic disease: a systematic review and meta-analysis. Br J Sports Med. (2014) 48:1227– 34.
Guzman A, Navarro E, Obando L, Pacheco J, Quiros K, Vasquez L, et al. Effectiveness of interventions for the reversal of a metabolic syndrome diagnosis: an update of a meta-analysis of mixed treatment comparison studies. Biomedica. (2019) 39:647–62.
Publicado
2024-05-23
Cómo citar
Lizarzábal García, M. (2024). Intestino permeable. Importancia para la salud y bienestar: Leaky gut. Importance for health and well-being. Revista Profesional HígadoSano, (27), 11-15. https://doi.org/10.5281/zenodo.11265113
Número
Sección
Artículos
